Paroxetine controlled release compositions

• US 7,229,640 B2
• Filed: 12/18/2001
• Issued: 06/12/2007
• Est. Priority Date: 07/20/1995
• Status: Expired due to Fees

• Current Assignee: Smithkline Beecham (Cork) Limited (Glaxosmithkline Holdings Ltd.)
• Original Assignee: Smithkline Beecham PLC
• Inventors: Elder, David Philip, Leonard, Graham Stanley
• Primary Examiner(s): Sheikh; Humera N.
• Application Number:
  US10/024,858
• Publication Number:
  US 20020090394A1
• Time in Patent Office: 2,002 Days
• Field of Search: 424/464, 424/465, 424/468, 424/472, 424/474, 424/482, 424/451, 424/457, 424/475, 424/476, 424/484, 424/458, 424/459
• US Class Current: 424/464
• CPC Class Codes: A61K 31/4525 containing a five-membered ring with oxygen as a ring hetero atom
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61K 9/2086 Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat active cores with a complete drug-free outer coat A61K9/28
• CPC Class Codes: A61K 9/2866 Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core

Abstract

A controlled release or delayed release formulation contains a selective serotonin reuptake inhibitor (SSRI) such as paroxtine.

Claims

1. A composition, that reduces the incidence of nausea and vomiting associated with the administration of paroxetine, comprising paroxetine, or a pharmaceutically acceptable salt thereof, in a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases the paroxetine predominantly in the small intestine.

2. A method of treating one or more disease states selected from;

Alcoholism, Anxiety, Depression, Obsessive Compulsive Disorder, Panic Disorder, Chronic Pain, Obesity, Senile Dementia, Migraine, Bulimia, Anorexia, Social Phobia, Pre-Menstrual Syndrome (PMS), Adolescent Depression, Trichotillomania, Dysthymla and Substance Abuse, which comprises administering an effective amount of a controlled and delayed release swallow pharmaceutical formulation that, upon administration, releases paroxetine or a pharmaceutically acceptable salt thereof, predominantly in the small intestine to an individual in need thereof.